Approval · Notice of Compliance 223 · 2002
FOSAMAX: Notice of Compliance 223
Issued February 4, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 223
- Date
- February 4, 2002
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strength: 70mg; new dosing regimen: once weekly; for the treatment of osteoporosis in postmenopausal women and in men
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FOSAMAX | 02245329 | Marketed |
Medicinal ingredients
- ALENDRONATE SODIUM 70 MG per TAB